Protagonist Therapeutics (NASDAQ:PTGX) Lowered to “Hold” at Zacks Investment Research
Zacks Investment Research lowered shares of Protagonist Therapeutics (NASDAQ:PTGX) from a strong-buy rating to a hold rating in a research note issued to investors on Thursday, January 4th.
According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “
A number of other equities research analysts have also commented on the company. BMO Capital Markets lowered their price target on Protagonist Therapeutics from $45.00 to $40.00 and set an outperform rating for the company in a research report on Thursday, October 19th. BidaskClub lowered Protagonist Therapeutics from a buy rating to a hold rating in a research report on Tuesday, December 12th. Finally, ValuEngine lowered Protagonist Therapeutics from a hold rating to a sell rating in a research report on Monday, September 11th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Protagonist Therapeutics presently has a consensus rating of Hold and an average price target of $32.50.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Monday, November 6th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.40. The firm had revenue of $8.78 million for the quarter.
In other news, insider David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $16.97, for a total transaction of $118,790.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dinesh V. Ph D. Patel sold 1,790 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $19.55, for a total value of $34,994.50. Following the sale, the insider now owns 192,227 shares of the company’s stock, valued at approximately $3,758,037.85. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,944 shares of company stock valued at $438,629. 15.50% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in PTGX. Rhumbline Advisers purchased a new position in shares of Protagonist Therapeutics during the 2nd quarter valued at about $114,000. Bank of Montreal Can increased its stake in Protagonist Therapeutics by 1,086.0% in the 4th quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock worth $123,000 after purchasing an additional 5,430 shares during the period. Wells Fargo & Company MN increased its stake in Protagonist Therapeutics by 60.8% in the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after purchasing an additional 3,617 shares during the period. Teachers Advisors LLC increased its stake in Protagonist Therapeutics by 71.4% in the 2nd quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock worth $183,000 after purchasing an additional 6,757 shares during the period. Finally, California State Teachers Retirement System increased its stake in Protagonist Therapeutics by 8.5% in the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock worth $188,000 after purchasing an additional 1,300 shares during the period. 41.86% of the stock is currently owned by institutional investors.
WARNING: “Protagonist Therapeutics (NASDAQ:PTGX) Lowered to “Hold” at Zacks Investment Research” was published by Marea Informative and is owned by of Marea Informative. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.mareainformativa.com/protagonist-therapeutics-ptgx-cut-to-hold-at-zacks-investment-research-updated-updated-updated/126748/.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.